GIMAP8

Across TCGA pan-cancer cohorts, GIMAP8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GIMAP8 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GIMAP8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GIMAP8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and COAD are the cancer types where GIMAP8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.889	1.000	.004	17	view →
LUAD	DFS	Quartile	All	0.884	0.506	.001	10	view →
COAD	DFS	Quartile	III,IV	0.791	1.000	.049	6	view →
PDAC	DFS	Quartile	All	0.947	0.676	.013	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.640	0.312	.036	4	view →
GBM	DFS	Tertile	All	0.276	0.416	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GIMAP8–HNSC (DFS)

Open the HNSC breakdown →